What are the key bottlenecks preventing rapid adoption of novel technologies?
Our latest Pharma's Almanac commentary features David Kang, Director of DI Governance, discussing the bottlenecks slowing advanced biomanufacturing adoption. Despite the promise of digital twins and automated processing, three key barriers stall industry-wide transition: regulatory uncertainty for unproven platforms, the high capital cost of retrofitting legacy facilities, and a talent gap bridging bioprocessing with data science.
Read our full commentary to learn how we can overcome these barriers.
Our latest Pharma's Almanac commentary features David Kang, Director of DI Governance, discussing the bottlenecks slowing advanced biomanufacturing adoption. Despite the promise of digital twins and automated processing, three key barriers stall industry-wide transition: regulatory uncertainty for unproven platforms, the high capital cost of retrofitting legacy facilities, and a talent gap bridging bioprocessing with data science.
Read our full commentary to learn how we can overcome these barriers.
Share article
Related Content